© 2026 Sinochem Nanjing Corporation,
All Right Reserved
The story of Mavacamten comes from a real place—a need to address hypertrophic cardiomyopathy, a condition that often pushes the heart to work harder than it should. For decades, doctors leaned on beta-blockers, calcium channel blockers, and sometimes even risky surgeries. Families lived with uncertainty, hoping for something more targeted and reliable. Around the turn of the 21st century, genetic understanding of cardiomyopathies began to sharpen. Researchers zeroed in on the proteins regulating heart muscle contraction, and attention shifted to myosin modulation. Mavacamten emerged from this era, showing early promise in experimental labs. Researchers didn’t just stumble on it: they understood the myosin path, designed compounds and re-designed them, moving step by step until early Mavacamten prototypes showed clearer results in both petri dishes and animal models. Commitment to public health and investment in molecular innovation fueled its journey through preclinical studies and landmark trials, ultimately earning regulatory breakthroughs and becoming a beacon in precision cardiac care.
Mavacamten represents a selective myosin inhibitor. Its fundamental action slows down the overzealous squeeze of heart muscle, particularly useful in obstructive hypertrophic cardiomyopathy. The drug comes as a white to off-white powder, handled and distributed mainly as oral capsules. Pharmaceutical companies spent years finetuning formulations, making sure patients get consistent dosing at 2.5 mg, 5 mg, 10 mg, and 15 mg strengths. Capsules are always stored in tight, light-resistant containers, at controlled room temperature, because the molecule’s stability depends on it. Health care providers prescribing Mavacamten take their cues from growing clinical data: trials like EXPLORER-HCM and VALOR-HCM have shown symptom relief and improved exercise capacity in patients who often felt out of options.
Mavacamten doesn’t just stand out for what it does inside the body; the physical and chemical details guide every step from manufacturing to patient care. Its molecular formula clocks in at C15H19N3O2, with a molecular weight of 273.33 g/mol. The compound’s crystalline nature impacts how it dissolves and therefore how quickly patients’ systems absorb the drug. Melting point ranges close to 222-226°C, and solubility can shift with temperature and solvent—in water its solubility is low, but manufacturers manage this by incorporating excipients to improve oral bioavailability. Chemists designed the molecule with specific stereochemistry to lock in activity and avoid unwanted side effects seen in less selective cardiac agents. Early efforts at scaling up synthesis also focused on these attributes, ensuring every batch matches pharmaceutical-grade expectations.
Patients and pharmacists reading a Mavacamten box see more than just a name. Labels confirm the strength, lot number, and expiration date; every bottle includes the standard EN6 warning—keep out of reach of children, do not crush or chew, and always follow prescribed dosing schedules. Cardiac monitoring recommendations now sit front-and-center on the label, a lesson learned from observing how Mavacamten interacts with other cardiac medications and the reality of fluctuating left ventricular ejection fractions. Labeling also lists contraindications, like use with certain CYP2C19 or CYP3A4 inhibitors, and systems for tracking adverse reactions. Every pharmaceutical distributor tracks chain of custody through barcodes, and hospital pharmacies rely on digital records to integrate these safety measures into everyday clinical decisions.
Manufacturers do not take shortcuts making Mavacamten. Most routes build the molecule through a stepwise condensation of an appropriately substituted amino acid derivative with a pyrazole carboxamide scaffold. As scaling up advanced, teams prioritized reactions that limit generation of hazardous byproducts—catalysts, solvents and temperatures all matter. After main synthetic steps, purification by recrystallization and column chromatography becomes vital to hit the purity standards required by regulatory agencies. Each batch passes through analytical tests—HPLC, mass spectrometry, and NMR—to confirm that no unwanted isomers, impurities, or residual solvents linger. Chemists often tweak steps to increase yield or lower production costs, but purity and chemical integrity remain non-negotiable.
The reactivity built into Mavacamten’s structure determines how it acts once inside the bloodstream. Its core pyrazole ring and securely attached side chains mean it resists random metabolism, extending its half-life in a controlled way. Chemists discovered salt forms that improve processing or shelf-life, but only the free base moves into the capsule. Drug designers spent years testing modifications: adding fluoro or methyl groups, or shifting amides, looking for gains in potency or selectivity. Teams published results on how these changes altered pharmacokinetics, feeding those insights back into next-generation drug design. Researchers still study how the molecule breaks down in the liver, ensuring that no harmful metabolites linger or interact with other cardio drugs that patients commonly take.
Anyone searching scientific databases or pharmacy shelves will see Mavacamten listed under its INN, but chemists know it by MYK-461 during its early clinical trial days. In the US, it’s branded as Camzyos®, a name now familiar in cardiology clinics. Investigators sometimes use structure-based labels: (R)-2-(4-(4-methyl-5-oxo-4,5-dihydro-1H-pyrazol-3-yl)phenyl)propanoic acid. Trade names earn regulatory approval only after quality, efficacy, and safety check every box. Cross-referencing these synonyms matters for pharmacists, especially in hospital settings juggling multiple suppliers and international shipments.
Handling Mavacamten starts with detail: gloves and dust masks in pharmaceutical plants during powder transfer, with strict controls on airborne particulates. Safety data sheets—available to every worker and clinician—document potential risks, from eye irritation in production to hypothetical mutagenicity highlighted by preclinical testing. Hospitals require patient-specific dosing and limit use if liver function drops, since liver enzymes play a major role in clearing the drug. Nurses and pharmacists lean on barcoded medication administration (BCMA) systems to track every dose and help spot potential interactions. Ongoing patient monitoring—echocardiograms and lab tests—keeps everyone alert to drops in heart function. Pharmacies provide patient information leaflets emphasizing these precautions, and updated electronic records record every adverse event. Clinical trial oversight boards re-examine safety data year after year, updating protocols as real-world results come in.
Doctors prescribe Mavacamten to people with symptomatic obstructive hypertrophic cardiomyopathy, those who feel short of breath just walking into the kitchen. It offers a less invasive approach compared to septal ablation or open-heart surgery, and gives new options for patients unable to tolerate old-guard drugs. Some cardiologists start patients on Mavacamten before considering defibrillator implants, hoping to avoid surgical risks. Specialist heart centers use it as part of personalized care plans, combining close cardiac monitoring, genetic counseling, and coordinated follow-ups with pharmacists and primary care. Nurses see a quality-of-life improvement as patients report walking farther and living fuller lives with fewer heart palpitations and dizzy spells. Clinical guidelines now mention Mavacamten, reflecting how trials shifted the standard of care for HCM.
Mavacamten’s story in the lab isn’t over. Research teams keep mapping how myosin inhibition reshapes heart muscle structure over months and years, and whether combining Mavacamten with gene therapy could help even more patients. Clinical trials continue to run across the globe, collecting data on use in non-obstructive HCM, different ethnic groups, and broader cardiac diseases like diastolic heart failure. Digital health tools, wearable monitors, and AI-driven cardiac imaging offer new insights into how the drug affects daily life and long-term outcomes. Pharmacoepidemiologists also mine big health datasets, cross-checking rare adverse events and long-term survival patterns to catch signals regulators can act on. Data sharing among research hospitals and the pharmaceutical industry speeds up discovery while helping regulators keep guidelines current.
Toxicologists ran battery after battery of tests before Mavacamten reached patients. Animal studies flagged precise heart, liver, and kidney markers to follow in people. Researchers tracked for arrhythmias or sudden blood pressure shifts, mapping out safe dose ranges. Later phase clinical trials spent years combing for rare but serious heart failure episodes or life-threatening drug-drug interactions. Regulatory filings included all this data, informing daily dosing recommendations and monitoring protocols. Every year, post-market surveillance adds to this database, so clinicians always have the best information when weighing risks and benefits for their patients.
Mavacamten carves a path for targeted therapies in heart disease, but it also asks researchers, doctors, and regulators to keep learning and sharing. Personalized dosing—as driven by genomics or early imaging—could make treatment even safer and more effective, reducing side effects while maximizing benefit. Companies already develop related molecules with tweaks to improve how fast the drug starts or how long it stays in the system. Application may spread to other heart conditions involving myosin overactivity, bringing new possibilities for patients whose current options fall short. As access broadens and prices gradually come down, conversations between patients, doctors, and insurers will shape real-world impact. The drug’s journey from bench to bedside, built on careful science and clinical vigilance, reflects the best of what medical research offers.
I’ve watched friends battle heart disease. It’s a constant worry—they can’t run up stairs, enjoy sports, or even walk a city block without feeling out of breath. For people with hypertrophic cardiomyopathy (HCM), daily life often comes with chest pain, dizziness, or even fainting. Mavacamten brings new hope for these folks. Instead of just masking symptoms or focusing on risky surgery, it tackles the root problem—muscles in the heart thickening and getting too stiff to pump blood efficiently.
Doctors used to have a limited toolbox for HCM: beta-blockers, calcium channel blockers, maybe some procedures to thin out the heart wall. Mavacamten shifts the game. It blocks part of the heart muscle’s machinery—myosin. In HCM, myosin goes into overdrive, building more muscle, making it tough for blood to move. Mavacamten tames this process.
The FDA opened the door to Mavacamten in 2022 after seeing strong results. Clinical trials proved that it improves heart function, boosts exercise ability, and cuts down on scary symptoms. Even more important, it does this without increasing the risk of deadly arrhythmias. That’s a big departure from old treatments—which often came with their own laundry list of side effects.
Living with HCM, people describe never being able to catch their breath. Ordinary medications sometimes leave them drained or shivering with side effects. Mavacamten changes that. Reports show patients walking farther in six-minute tests, being able to do more for themselves, and feeling less anxious about heart “flare-ups.” Cutting back on surgeries—often an only option for severe HCM—brings huge relief. Open-heart surgery comes with long recovery, health risks, and massive costs. Having another option on the table makes a real difference in quality of life.
The best drugs won’t help if patients can’t get them. Right now, Mavacamten comes with a heavy price tag, landing on the higher end of new cardiac medications. Many insurers take time to approve it, if they cover it at all. Cardiology teams also need extra training to monitor patients, especially because the drug affects how the heart contracts. This means regular echocardiograms—no skipping appointments or ignoring new symptoms. Some patients, especially in rural or underfunded areas, still rely on older therapies simply because access isn’t there.
Improving care for HCM hinges on more than just a new pill. I see two things that make a dent: education and advocacy. Doctors and patients benefit when they know about these new options and how Mavacamten works. Nonprofits and patient organizations get the word out, helping people ask their doctors the right questions. Insurance companies and policymakers also need pressure to cover newer, more effective treatments. As demand grows, prices may come down—or at least, more patients can join studies or assistance programs.
The world isn’t short on heart disease. That makes drugs like Mavacamten not just a medical breakthrough, but a real-life bridge to longer, healthier living for a community that’s waited too long on the sidelines.
People living with hypertrophic cardiomyopathy know life can feel like a tight squeeze. The heart muscle thickens, making it hard for blood to flow. That thickened muscle grabs every bit of energy to contract, but it forgets how to relax. Shortness of breath, chest pain, and even fainting become a part of daily life. Families watch their loved ones wrestle with these symptoms, hoping for something that gives lasting relief. Traditional medications, like beta-blockers, often ease the pressure but rarely make anyone feel normal again.
Mavacamten steps into this story with something novel. It targets the core problem, not just the symptoms. Mavacamten isn’t just calming the heart down. It works on the microscopic machinery of the heart muscle, the myosin heads, which act like thousands of microscopic hands pulling the muscle fibers tight. In hypertrophic cardiomyopathy, those hands grab too tightly and too often, creating the thickness that makes the heart misbehave.
The researchers who built Mavacamten saw that if you tell some of these myosin heads to rest, the muscle won’t thicken as much. Imagine you’re trying to clean up after a family dinner, and ten people all try to scrub the same plate at once—they get in each other’s way. Mavacamten tells a few of those helpers to take a seat. Now, only five hands are at work, and the job moves along smoothly. By blocking some of those myosin heads from pushing the muscle, the heart gets a chance to relax and pump more efficiently.
People I’ve spoken with who deal with hypertrophic cardiomyopathy tell me how fatigue shadows their days. Mavacamten, backed by clinical trials, seems to change the landscape for these folks. Studies, such as the EXPLORER-HCM trial, show improvement in exercise ability and symptoms. Participants could walk further and breathe easier. Doctors saw clear changes using echocardiograms, signaling that the heart’s function shifted for the better.
No new treatment comes without questions. Some worry about side effects since shutting down too many myosin heads might lead to heart weakness. Close monitoring with regular tests, including echocardiograms, becomes part of the plan. People have to work with doctors who understand this approach and can spot trouble early. For many, the possibility of feeling more energetic outweighs these risks, but it pays to stay informed and aware.
Mavacamten steps away from traditional treatments, which mostly hide symptoms under a rug. With new ideas that come from understanding the heart’s smallest moving parts, doctors can offer treatments that seem to fit the cause, not just the pain. The arrival of drugs like Mavacamten shows how science keeps pushing forward, listening to what patients need, and giving families hope for more active and less fearful lives. We’ll need to keep learning, watch patients closely, and share real-world stories as this medicine becomes more common.
Mavacamten, a medication for obstructive hypertrophic cardiomyopathy, has sparked interest because of its targeted action on the heart muscle. People living with this heart condition hold out hope for new options, but also want clarity about what life feels like while taking this drug. Most folks in the community talk about their own reactions and compare notes about changes, both good and not so great. Healthcare providers and researchers take these experiences seriously, often including direct feedback in their recommendations.
Fatigue seems to lead the list. I remember the first stories circulating online: people saying they felt washed out, especially soon after starting the medication. Fatigue isn’t just a minor annoyance for someone who already deals with a tired heart; it gets in the way of daily responsibilities and can sometimes prompt a call to the doctor. Dizziness comes next, which can show up without warning whether sitting, standing, or getting up quickly. Falling or nearly losing balance creates worry, and this isn’t something anyone wants to brush aside.
A few posts in support groups mention feeling short of breath. For some, Mavacamten helps breathing over the long run, but others report days that feel tougher, with a tight chest or slightly more breathlessness than usual. Being honest about this with healthcare providers matters, especially for people juggling several heart medicines. My own conversations with affected families make clear that tracking these changes on a calendar can be a real help during check-ins.
Mavacamten changes how heart muscle works, so not every pulse beat feels steady. Some folks describe skipped beats, stronger thumps, or short bursts of fast heart rate. While irregular heartbeats (arrhythmias) belong as a possible side effect, many doctors recommend monitoring at home. Wearable devices and blood pressure monitors help people log patterns and share this history with their cardiologist instead of relying on memory alone.
Doctors stress the importance of dosing Mavacamten carefully and following up with regular check-ins. Too much medication lowers the heart’s pump strength. This can show up as leg swelling, weight gain, feeling winded while lying flat, or even waking up gasping for air. These signs start conversations about whether dosage changes or extra hospital visits are necessary. I have seen friends keep an eye on their ankles each morning and weigh themselves twice a week, tools which work as early warning systems.
Before starting Mavacamten, and then off and on during treatment, liver blood tests check for early warning signs. Most people won’t notice liver trouble without those tests, making routine lab work essential. Yellowing of the eyes, stomach pain, or dark urine should lead right to a doctor’s office.
Better communication with health teams stands out as a way to catch trouble early. People who keep a record of what they feel—tiredness, dizziness, changes in breathing—often get better support. Small fixes, like changing the time of day the pill is taken or adjusting other medications, sometimes lessen the load. Routine heart imaging, wearable monitors, and regular in-person checkups help keep treatment on track. A collaborative approach, with patient and medical team each sharing information, gives the best shot at handling these effects before they turn serious.
Mavacamten came onto the scene offering hope for people struggling with obstructive hypertrophic cardiomyopathy. This heart condition can make simple tasks exhausting. Mavacamten offered a way to address the underlying muscle problem, not just control symptoms. Not everyone can benefit, though, and taking it without care risks doing harm.
This medication works by relaxing an overactive heart muscle. That feature gives it its power, but it also creates a set of dangers. Folks whose hearts already pump too weakly, such as those with a low ejection fraction, face real risks. The heart might not push out enough blood, leading to more severe symptoms or even heart failure. Clinicians look for an ejection fraction above 55% before considering Mavacamten. People below that line need a different approach.
Drugs clear out of the body through the liver. For Mavacamten, the liver acts as the main processing center. If someone's liver doesn't work right — thinking of those with cirrhosis, hepatitis, or similar liver concerns — the drug can linger, building up to unexpected levels. This situation raises the odds of dangerous side effects, including further slowing of the heart's contraction. People with liver disease need a plan built around the limits of their bodies. Studies show liver impairment slows drug clearance in noticeable ways.
It's easy to downplay drug interactions, but some medicines don’t play nice. Strong CYP2C19 or CYP3A4 inhibitors — drugs that block major liver enzymes, such as fluconazole (used for fungal infections) or some antibiotics — keep Mavacamten in the blood longer than it should be. That buildup risks heart complications. The same warning flashes for inducers like rifampin, which push the drug out too fast, stripping away its effect. People asked to take these other drugs may need a swap or careful medical supervision.
Expecting mothers face a tough reality here. Animal studies point to harm for developing babies. No one wants to find out the hard way. The FDA labels Mavacamten as a pregnancy risk for good reason. For women of childbearing age, contraception isn’t optional while taking it. Anyone planning a family soon should steer clear until more is known. Obstetricians I’ve talked to express real nervousness about unknowns here.
Allergic reactions can prove serious fast. If someone’s had a bad reaction to Mavacamten before, even if it seemed mild, trying again isn’t safe. While rare, these responses can escalate on a repeat exposure.
People with fluctuating heart rhythms, those who can’t get regular heart imaging, or anyone without access to consistent healthcare, might not be able to take Mavacamten safely. Cardiologists depend on echocardiograms and close checkups to keep dosing just right and catch early signs of trouble. Without that level of monitoring, the risks start to outweigh the benefits.
Mavacamten isn’t for every heart muscle problem. Other forms of cardiomyopathy, such as dilated or restrictive types, won’t see the same help. Using it in these groups isn’t just unproven — it poses unjustifiable danger.
In short, powerful new treatments like Mavacamten demand careful selection. The goal stays the same: more living, less suffering — but for some, another road makes more sense.
Mavacamten, which doctors prescribe for adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM), has changed the outlook for many who live with this challenging heart condition. It targets the underlying source of obstruction—too many cross-bridges locking up the heart muscle—rather than just managing symptoms. Not many breakthroughs in heart medicines have shifted my view of treating HCM as much as this one.
You swallow Mavacamten as a capsule. You take it once a day, and you don’t crush or chew it—the capsule goes down whole with water, usually at the same time each day. Many people remember to take their medicine better if they slot it into a morning or evening routine. I always remind folks that food doesn’t matter with Mavacamten. You can take it with a meal or on an empty stomach, which takes away at least one worry for people who juggle complicated routines.
The typical starting dose sits at 5 mg once daily. Dosage doesn’t stay fixed, though. Doctors adjust the dose based on how much Mavacamten affects your heart—a process monitored with regular heart ultrasound scans (echocardiograms) and blood work to measure drug levels. Sometimes, people bump up to 10 mg or 15 mg daily, or even dial back to 2.5 mg based on how their heart responds or if side effects crop up. The dosing decisions depend on real numbers: your left ventricular outflow tract gradient, how you’re feeling, and how your body processes the drug.
Doctors watch for more than symptom relief. They keep tight tabs on heart function because pushing the dose too high may weaken the heart muscle too much. Patients coming into clinic for these check-ups usually get an echocardiogram and blood tests every few weeks at first, then less often as things settle out. If your ejection fraction drops below 50 percent, your doctor might pause the drug or lower the dose and wait for things to rebound. Missing this careful monitoring can mean trouble, so regular visits aren’t just a formality—they anchor your safety.
Mavacamten interacts with certain other medicines. Some antifungals, antibiotics, and even grapefruit juice can change how your body handles the drug. That’s not something you spot by guesswork—experience tells me this needs honest conversations with your healthcare team. Always run new medicines or supplements past a pharmacist or doctor before mixing anything with Mavacamten.
The logistics of using Mavacamten—monthly trips for heart scans and blood draws, the questions about drug interactions—feel like another layer of stress for families already carrying a heart condition. I’ve seen many people struggle with medical complexity, not the medicine itself. One step that helps: using reminders, setting up visits way in advance, and working closely with a team who know your story.
Mavacamten doesn’t cure hypertrophic cardiomyopathy outright, but it moves the needle for many people who have spent years watching their activity, dodging symptoms, or facing surgery. Knowing how it’s taken, why the dose changes, and what to watch for anchors people in the process. Connecting with others who take the medication—through support groups or clinics—can also make the road less lonely, adding human support to medical science.
| Names | |
| Preferred IUPAC name | (3-(4-{1-[(4-cyanophenyl)amino]cyclopropyl}phenoxy)-5-isopropyl-1,2,4-oxadiazol-1-yl)acetic acid |
| Other names |
MYK-461 Camzyos |
| Pronunciation | /ˌmævəˈkæmtən/ |
| Identifiers | |
| CAS Number | 1642288-47-8 |
| Beilstein Reference | 3587263 |
| ChEBI | CHEBI:145312 |
| ChEMBL | CHEMBL2103886 |
| ChemSpider | 160963 |
| DrugBank | DB15197 |
| ECHA InfoCard | DB15661 |
| EC Number | EC 2.7.11.1 |
| Gmelin Reference | 1304475 |
| KEGG | D12525 |
| MeSH | D000077633 |
| PubChem CID | 11505311 |
| RTECS number | WHI7ZT7H6C |
| UNII | G9WDO795OL |
| UN number | UN3549 |
| CompTox Dashboard (EPA) | DTXSID50801060 |
| Properties | |
| Chemical formula | C15H19N3O4 |
| Molar mass | 666.808 g/mol |
| Appearance | White to pale yellow powder |
| Odor | Odorless |
| Density | 1.19 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | 1.98 |
| Acidity (pKa) | 13.4 |
| Basicity (pKb) | 12.05 |
| Magnetic susceptibility (χ) | NA |
| Refractive index (nD) | 1.548 |
| Dipole moment | 3.5 Debye |
| Thermochemistry | |
| Std molar entropy (S⦵298) | Std molar entropy (S⦵298) of Mavacamten: 576.3 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | −13.6 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -6865 kJ/mol |
| Pharmacology | |
| ATC code | C01EB25 |
| Hazards | |
| Main hazards | Heart failure, left ventricular dysfunction, teratogenicity |
| GHS labelling | GHS07, GHS08 |
| Pictograms | Cardiac disorders, Hepatotoxicity, CYP interactions |
| Signal word | Warning |
| Hazard statements | Hazard statements: "H360 May damage fertility or the unborn child. |
| Precautionary statements | Carcinogenicity; Reproductive toxicity; Effects on blood pressure, heart rate, and cardiac contractility |
| Flash point | > Not hazardous. |
| LD50 (median dose) | LD50 (median dose): >2000 mg/kg (rat, oral) |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for Mavacamten is not established. |
| REL (Recommended) | 15 mg |
| IDLH (Immediate danger) | Not Established |
| Related compounds | |
| Related compounds |
Aficamten CK-136 Dantrolene Omecamtiv mecarbil |
